DNA tests provider Prenetics Global's Q2 revenue up 594.9%, shares jump

Prenetics Global

12/09/2025 13:44

Overview

Prenetics Q2 2025 revenue grows 594.9% yr/yr but misses analyst expectations

Co increases FY2025 revenue guidance to $85-100 mln, aims for break-even Q1 2026, shares up 16.7% premarket

Prenetics adds 228 Bitcoin to treasury, reflecting strategic financial initiative

Outlook

Prenetics increases FY2025 revenue guidance to $85 - $100 mln

Company expects to achieve breakeven by Q1 2026

Result Drivers

IM8 GROWTH - IM8 brand achieved $9.8 mln in Q2 revenue, up 70% from Q1, driven by strong customer acquisition and brand awareness

BITCOIN STRATEGY - Co added 228 Bitcoin to its treasury, reflecting a strategic financial initiative to enhance long-term value

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
Miss
$17.70 mln
$21.70 mln (1 Analyst)
Q2 Adjusted EBITDA
-$4.10 mln


Analyst Coverage

The one available analyst rating on the shares is "buy"

Wall Street's median 12-month price target for Prenetics Global Ltd is $14.00, about 36.7% above its September 11 closing price of $8.86

Press Release: ID:nGNX8NpNX9

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)